Prevalence and distribution of carbapenem‐resistant Enterobacterales in companion animals: A nationwide study in the United States using commercial laboratory data

Abstract

AbstractBackgroundCarbapenem‐resistant Enterobacterales (CRE) are a concern in both human and animal medicine globally. Despite extensive research in humans, limited data exist on CRE in companion animals, with a lack of nationwide prevalence estimates.Hypothesis/ObjectivesTo assess the occurrence and trends of CRE in cats and dogs across the United States by analyzing 4 years of commercial antimicrobial susceptibility testing (AST) data.AnimalsBetween 2019 and 2022, 477 426 ASTs were conducted on Enterobacterales isolates against imipenem. Isolates were derived from 379 598 dogs and 97 828 cats. Animal origin was not disclosed.MethodsIn this retrospective study, antimicrobial susceptibility test data from IDEXX Laboratories were analyzed. Analysis included resistance estimations to imipenem stratified by sampling site, an assessment of resistance patterns over time and location, and the application of space‐time cluster analysis to identify potential outbreaks. Antibiograms were produced for carbapenem‐resistant isolates.ResultsSusceptibility to imipenem was high, at 98.86%. Temporal analysis indicated stability in susceptibility, with an unexplained reduction in susceptible isolates in June 2019. Spatial analysis identified 2 high‐risk clusters along the Western Coast (relative risk [RR]: 23.26; P < .001) and in Texas (RR: 10.72; P < .001) in that month. Three other clusters were found, in Missouri (RR: 39.55; P = .038), Florida (RR: 4.53; P < .001), and New York (RR: 9.20; P < .001).Conclusions and Clinical ImportanceCRE are present at a low prevalence in dogs and cats across the United States. Variations in prevalence across patient‐level and environmental factors highlight the need for tailored stewardship programs.